Brief: Surface Oncology Announces Phase 2 Study Testing SRF388 In Hepatocellular Carcinoma With Roche
04/10/2021 12:16
Oct 4 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES NEW RANDOMIZED PHASE 2 CLINICAL
STUDY
EVALUATING SRF388 IN PATIENTS WITH FIRST-LINE HEPATOCELLULAR
CARCINOMA IN CLINICAL COLLABORATION WITH ROCHE
* SURFACE ONCOLOGY INC - INITIATION-ENABLING ACTIVITIES ARE
UNDERWAY, AND COMPANY EXPECTS TO DOSE FIRST PATIENT IN EARLY
2022.
Source text for Eikon: ID:nGNX2gKrjX
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing